Hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: Prospective randomized study

Hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: Prospective randomized study - HAIC for advanced HCC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005731

Enrollment

Registered

2011-09-01

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced hepatocellular carcinoma

Interventions

Combination therapy with desferoxamine and sorafenib Sorafenib only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with advanced hepatocellular carcinoma 2) Non-responders for chemotherapy with anticancer drugs and indication for sorafenib 3) Patients who have no influence on previous treatment 4) Performance status(PS) 0 or 1 5) Child-Pugh A 6) Favorable function of major organs (bone marrow, kidney, heart), and meeting citeria as follows: (1) neutrophil count >= 1500/mm3 (2) platelet count>= 50000/mm3 (3) hemogrobin level >= 8.5g/dl (4) serum creatinine level < 2mg/dl (5) prothrombin time activity >= 50% (6) age >= 20years, male and female

Exclusion criteria

Exclusion criteria: 1) Severe coexisting illness (expect for chronic hepatitis or liver cirrhosis) 2) Active bouble cancers 3) serum creatinine level >= 2mg/dl 4) Past history of hypersensitivity for drugs including iodine and contrast agent 5) Patients with pregnancy, lactation or possibility of pregnancy 6) Patients who judged as inadequacy due to other reasons by the doctor

Design outcomes

Primary

Measure	Time frame
Survival	—

Secondary

Measure	Time frame
Response, Progression-free survival, Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026